Revelation Biosciences, Inc.
$1.16
▲
1.63%
2026-04-21 09:07:01
www.revbiosciences.com
NCM: REVB
Explore Revelation Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.32 M
Current Price
$1.16
52W High / Low
$43.48 / $0.99
Stock P/E
—
Book Value
$5.59
Dividend Yield
—
ROCE
-94.64%
ROE
-1.31%
Face Value
—
EPS
$-23.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
-0.17
Debt / Equity
8.43
Current Ratio
5.41
Quick Ratio
5.41
Forward P/E
-0.36
Price / Sales
—
Enterprise Value
$-5.66 M
EV / EBITDA
0.63
EV / Revenue
—
Rating
Strong Buy
Target Price
$19.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 2. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
| 3. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 4. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 5. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 6. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 7. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.57 M | -1.94 M | -2.46 M | -2.09 M | -1.75 M | — |
| Net Profit | -2.51 M | -1.91 M | -2.44 M | -2.05 M | -1.73 M | — |
| EPS in Rs | -0.67 | -0.51 | -0.66 | -0.55 | -0.46 | -160.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -9.07 M | -7.98 M | -8.66 M | -10.86 M |
| Net Profit | -8.91 M | -15.04 M | -0.12 M | -10.83 M |
| EPS in Rs | -2.4 | -4.04 | -0.03 | -2.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.58 M | 6.62 M | 12.21 M | 5.5 M |
| Total Liabilities | 2.72 M | 1.91 M | 5.56 M | 4.45 M |
| Equity | 8.86 M | 4.71 M | 6.65 M | 1.05 M |
| Current Assets | 10.81 M | 6.57 M | 12.15 M | 5.41 M |
| Current Liabilities | 2 M | 1.91 M | 5.56 M | 4.45 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.27 M | -18.32 M | -7.29 M | -11.22 M |
| Investing CF | 0 M | -0.02 M | 0 M | 0 M |
| Financing CF | 12.47 M | 12.85 M | 14.03 M | 15.2 M |
| Free CF | -8.27 M | -18.34 M | -7.29 M | -11.22 M |
| Capex | — | -0.02 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 40.73% | -12405.64% | 98.89% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-28 | 1:0.25 |
| 2025-07-07 | 1:0.333333 |
| 2025-01-28 | 1:0.0625 |
| 2024-01-25 | 1:0.0333333 |
| 2023-02-01 | 1:0.0285714 |